Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.81)
# 1,766
Out of 4,883 analysts
80
Total ratings
45.76%
Success rate
7.38%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Initiates: Hold | $22 | $20.88 | +5.36% | 16 | Feb 11, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $10.74 | +39.66% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $6.76 | +18.34% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $16.43 | +204.32% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $127.88 | +6.35% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $3.31 | +383.38% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $6.30 | +884.91% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.45 | +727.59% | 6 | Dec 12, 2023 | |
| SAGE Sage Therapeutics | Initiates: Hold | $21 | $9.16 | +129.38% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $17.32 | +529.33% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.16 | +592.64% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.75 | +263.64% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $5 | $0.43 | +1,054.73% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $3.71 | +61.73% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $3.26 | +544.17% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $96.95 | -76.28% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $23.46 | +53.49% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
Feb 11, 2025
Initiates: Hold
Price Target: $22
Current: $20.88
Upside: +5.36%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $10.74
Upside: +39.66%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $6.76
Upside: +18.34%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $16.43
Upside: +204.32%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $127.88
Upside: +6.35%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $3.31
Upside: +383.38%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $6.30
Upside: +884.91%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.45
Upside: +727.59%
Sage Therapeutics
Dec 12, 2023
Initiates: Hold
Price Target: $21
Current: $9.16
Upside: +129.38%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $17.32
Upside: +529.33%
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.16
Upside: +592.64%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $2.75
Upside: +263.64%
Nov 11, 2022
Maintains: Buy
Price Target: $7 → $5
Current: $0.43
Upside: +1,054.73%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $3.71
Upside: +61.73%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $3.26
Upside: +544.17%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $96.95
Upside: -76.28%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $23.46
Upside: +53.49%